The latest price target for Iterum Therapeutics (NASDAQ:ITRM) was reported by HC Wainwright & Co. on June 21, 2024. The analyst firm set a price target for $6.00 expecting ITRM to rise to within 12 months (a possible 445.45% upside). 7 analyst firms have reported ratings in the last year.

The latest analyst rating for Iterum Therapeutics (NASDAQ:ITRM) was provided by HC Wainwright & Co., and Iterum Therapeutics reiterated their buy rating.

The last upgrade for Iterum Therapeutics PLC happened on February 7, 2024 when HC Wainwright & Co. raised their price target to $6. HC Wainwright & Co. previously had a neutral for Iterum Therapeutics PLC.

The last downgrade for Iterum Therapeutics PLC happened on July 26, 2021 when HC Wainwright & Co. changed their price target from N/A to N/A for Iterum Therapeutics PLC.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iterum Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iterum Therapeutics was filed on June 21, 2024 so you should expect the next rating to be made available sometime around June 21, 2025.

While ratings are subjective and will change, the latest Iterum Therapeutics (ITRM) rating was a reiterated with a price target of $6.00 to $6.00. The current price Iterum Therapeutics (ITRM) is trading at is $1.10, which is out of the analyst’s predicted range.